Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The United Laboratories International Holdings ( (HK:3933) ) has issued an announcement.
The United Laboratories International Holdings Limited announced that its Moxifloxacin Hydrochloride Eye Drops have received approval from the China National Medical Products Administration. This approval is expected to enhance the company’s ophthalmic portfolio and solidify its position in the field of ophthalmic anti-infective treatment, potentially leading to greater returns for the company and its shareholders.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited is a company incorporated in the Cayman Islands, primarily operating in the pharmaceutical industry. It focuses on developing and manufacturing a range of pharmaceutical products, with a particular emphasis on ophthalmic anti-infective treatments.
Average Trading Volume: 11,329,442
Technical Sentiment Signal: Buy
Current Market Cap: HK$25.49B
See more data about 3933 stock on TipRanks’ Stock Analysis page.